Drug Treats Painful Side Effect of Chemotherapy

	Tweet

The U.S. Food and Drug Administration has approved the Amgen intravenous drug Kepivance (palifermin) to prevent mucositis, a common side effect among blood cancer patients who have chemotherapy before bone marrow transplants.

Patients with mucositis, characterized by debilitating, painful sores in the lining of the mouth and throat, often have trouble eating, drinking and swallowing.

Some 11,000 adults with hematologic cancers—including non-Hodgkin’s lymphoma, Hodgkin’s disease, leukemia and multiple myeloma—have bone marrow transplants each year, Amgen said. The new drug works to stimulate the growth of cells in the mouth and throat that protect tissue from the harmful effects of chemotherapy and/or radiation.

The most common side effects of Kepivance use were skin rash, tingling sensations in the mouth and throat, and an increase in certain blood proteins that signal pancreatic irritation. None of these conditions is considered serious, the FDA said.

RELATED STORIES:
Effectiveness of bird flu vaccine debated   Onyx Shares Fall on Cancer Drug Filing   Actonel helps prevent hip fractures after stroke   Anti-parasite drugs effective in mothers, children   FDA adds restrictions to acne drug   Cautious Optimism for New Alzheimer’s Medications   Merck tried to bury Vioxx concerns for years   Cocoa-derived medicines still years away: experts   FDA advisory panel recommends adding warning label to Tamoxifen   Merck board names committee on Vioxx withdrawal   Anti-Hypertensive Drugs May Help Prevent and Treat Alzheimer’s Disease   Merck may settle some Vioxx cases, NJ trial looms

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]